Glaxo - Smith Kline and Pfizer pharmaceutical companies joined hands to set up AIDS
April 17, 2009 15:11:48 Source: Xinhua
     Xinhua New York, April 16 Xinhua British Glaxo - Smith Kline and the United States, the two well-known pharmaceutical company Pfizer on the 16th announced that it would set up a new company dedicated to the development and marketing of drugs against AIDS, with less investment expectations in the fight against AIDS drug market advantage.

     London-based Glaxo - SmithKline currently has several drugs against AIDS on the market, some of which is about to expire patent drugs. The New York-based Pfizer is developing new drugs to fight AIDS.

     According to the two sides issued a joint statement the same day, the two companies will integrate its AIDS drug-related resources, is expected to be completed in the fourth quarter of this year to form the new company.

     The newly established enterprises will have 11 sales in the market for AIDS drugs, is expected to occupy 19% of the expected global market share, second only to the U.S. company Gilead Science and Technology of market share. Currently, Bristol-Myers Squibb Company, Abbott Laboratories Inc., Merck & Co., Inc. are also AIDS drugs in research and development and marketing to compete.

     Market analysts believe that Glaxo - Smith Kline and Pfizer co-operation shows that pharmaceutical companies are increasingly focused on research and development focus on several AIDS drugs, and pay more attention to control R & D costs, a number of industry competitors to cooperate in the search for now in order to share the risks and costs of drug research and development.